CD3×CD20双特异性抗体治疗相关毒性管理的共识建议
靶向CD3和CD20的双特异性抗体(BsAb)为B细胞非霍奇金淋巴瘤带来新突破,但可导致细胞因子释放综合征(CRS)等严重毒性。鉴于其毒性特征与CAR-T疗法存在时序、性质和严重程度差异,国际专家组制定共识,针对CD3×CD20 BsAb相关毒性的评估与管理提出建议。
要点
- CD3×CD20 BsAb可导致T细胞激活相关的严重毒性,尤其CRS。
- BsAb毒性在时序、性质和严重程度上与CAR-T疗法不同。
- 国际专家组基于共识提出针对CD3×CD20 BsAb毒性的评估与管理建议。
核心结论
- 国际专家组针对CD3×CD20双特异性抗体相关毒性的评估与管理形成共识建议。
研究设计与样本
- 国际专家组由学术和社区执业医生、高级执业护士、注册护士及药师组成,具有临床试验和试验外使用CD3×CD20 BsAb的经验。
主要发现
- CD3×CD20 BsAb在重度经治患者中显示出显著的单药活性,已有3种药物在多个国家获得监管批准。
- BsAb可导致T细胞激活相关的严重毒性,尤其是细胞因子释放综合征(CRS)。
- BsAb与CAR-T细胞疗法毒性在时序、性质和严重程度上存在显著差异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bispecific antibodies (BsAb) that target CD3 and CD20 represent a new milestone in the treatment of patients with B-cell non-Hodgkin lymphoma. These drugs have demonstrated remarkable single-agent activity in patients with heavily pretreated disease, and 3 drugs have so far received regulatory approvals in various countries. However, BsAbs can potentially lead to severe toxicity associated with T-cell activation, particularly cytokine release syndrome (CRS). The anticipated widespread use of these off-the-shelf products poses challenges for implementation and highlights the need for guidance in anticipating, mitigating, and managing adverse events. In clinical trials, guidance for the evaluation and treatment of CRS and neurotoxicity associated with BsAb therapy has been modeled after algorithms originally created for chimeric antigen receptor (CAR) T-cell therapies and other immune effector therapies, yet notable differences in timing, quality, and severity exist between the toxicities of BsAbs and CAR T-cell therapies. We therefore convened an international panel of academic and community practice physicians, advanced practitioners, registered nurses, and pharmacists with experience using CD3×CD20 BsAbs in clinical trial and off-trial settings to provide comprehensive, consensus-based recommendations specific to the assessment and management of CD3×CD20 BsAb-related toxicities.
引用
- Crombie JL, Graff T, Falchi L, et al. Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Blood. 2024. PMID: 38252906. doi:10.1182/blood.2023022432
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。